Back to today’s briefing

Story perspectives

Biotech Funding Plummets Amid Investor Caution and Tariff Woes

7/18/2025

26 2

Summary

Story summary

In 2025, venture capital funding for private biotech companies plummeted from $2.6 billion to $900 million in initial financings.
Total funding decreased from $7 billion to $4.8 billion, the lowest quarterly total in three years.
Investor caution arose from tariff concerns and funding cuts, resulting in fewer but larger deals.
M&A activity held steady, with 17 drug startups acquired in 2024, suggesting potential investment returns.

1 of 1

Story summary

In 2025, venture capital funding for private biotech companies plummeted from $2.6 billion to $900 million in initial financings.
Total funding decreased from $7 billion to $4.8 billion, the lowest quarterly total in three years.
Investor caution arose from tariff concerns and funding cuts, resulting in fewer but larger deals.
M&A activity held steady, with 17 drug startups acquired in 2024, suggesting potential investment returns.